Marginal Zone Lymphoma
147
41
61
48
Key Insights
Highlights
Success Rate
68% trial completion
Published Results
38 trials with published results (26%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
15.6%
23 terminated out of 147 trials
67.6%
-18.9% vs benchmark
7%
10 trials in Phase 3/4
79%
38 of 48 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 48 completed trials
Clinical Trials (147)
FDG PET Evaluation for Marginal Zone Lymphoma and Its Prognostic Role
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma
Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor Therapy
Pemigatinib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas
Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (R/R B-NHL)
A Phase II Study Using Rituximab Plus Venetoclax in the Front Line Treatment of Marginal Zone Lymphoma
Allo HSCT Using RIC and PTCy for Hematological Diseases
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma
ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies
64Cu-LLP2A for Imaging Hematologic Malignancies
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)
Preliminary Assessment of [18F]BL40 in PET/CT Scans
Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell Lymphoma
Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone Lymphoma
Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma